UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Precision medicine for metastatic TNBC: the FUTURE is now

Cell research, 2023-07, Vol.33 (7), p.491-492

2023

Volltextzugriff (PDF)

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2

Journal of clinical oncology, 2020-02, Vol.38 (5), p.444-453

2020

Volltextzugriff (PDF)

Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27

Journal of clinical oncology, 2012-11, Vol.30 (32), p.3960-3966

2012

Volltextzugriff (PDF)

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

Journal of clinical oncology, 2011-09, Vol.29 (25), p.3366-3373

2011

Volltextzugriff (PDF)

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

Journal of clinical oncology, 2010-04, Vol.28 (10), p.1677-1683

2010

Volltextzugriff (PDF)

Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?

Journal of clinical oncology, 2019-09, Vol.37 (25), p.2196-2200

2019

Volltextzugriff (PDF)

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Annals of oncology, 2021-08, Vol.32 (8), p.1005-1014

2021

Volltextzugriff (PDF)

Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2466-2473

2009

Volltextzugriff (PDF)

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

Journal of clinical oncology, 2012-04, Vol.30 (12), p.1268-1273

2012

Volltextzugriff (PDF)

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy

Journal of clinical oncology, 2023-06, Vol.41 (16), p.2988-2997

2023

Volltextzugriff (PDF)

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

Journal of clinical oncology, 2006-08, Vol.24 (23), p.3726-3734

2006

Volltextzugriff (PDF)

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer

Journal of clinical oncology, 2023-07, Vol.41 (20), p.3565-3575

2023

Volltextzugriff (PDF)

Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

Journal of clinical oncology, 2006-05, Vol.24 (13), p.2019-2027

2006

Volltextzugriff (PDF)

Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer

JNCI : Journal of the National Cancer Institute, 2023-11, Vol.115 (11), p.1302-1309

2023

Volltextzugriff (PDF)

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

Breast cancer (Tokyo, Japan), 2023-07, Vol.30 (4), p.596-605

2023

Volltextzugriff (PDF)

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

The New England journal of medicine, 2005-10, Vol.353 (16), p.1673-1684

2005

Volltextzugriff (PDF)

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

Breast cancer research and treatment, 2011-05, Vol.127 (1), p.133-142

2011

Volltextzugriff (PDF)

Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials

Journal of clinical oncology, 2006-05, Vol.24 (13), p.2028-2037

2006

Volltextzugriff (PDF)

Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3197-3204

2013

Volltextzugriff (PDF)

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7811-7819

2005

Volltextzugriff (PDF)

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41

Breast cancer research and treatment, 2023-06, Vol.199 (2), p.243-252

2023

Volltextzugriff (PDF)

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial

Journal of clinical oncology, 2008-04, Vol.26 (12), p.1965-1971

2008

Volltextzugriff (PDF)

Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer

Journal of clinical oncology, 2011-11, Vol.29 (31), p.4160-4167

2011

Volltextzugriff (PDF)

1 – 25 von 190

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(167)
Mit Volltextzugriff
(169)

Publikationsform

Sprache

Englisch
(190)

Erscheinungsjahr

n.n

Thema

Science & Technology
(139)
Life Sciences & Biomedicine
(136)
Humans
(121)
Female
(103)
Oncology
(103)
Middle Aged
(62)
Breast Neoplasms - Drug Therapy
(61)
Adult
(51)
Breast Cancer
(49)
Aged
(43)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(41)
Biological And Medical Sciences
(40)
Breast Neoplasms - Pathology
(39)
Medical Sciences
(39)
Chemotherapy
(36)
Chemotherapy, Adjuvant
(36)
Male
(34)
Treatment Outcome
(31)
Tumors
(30)
Disease-Free Survival
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Precision medicine for metastatic TNBC: the FUTURE is now

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2

Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer

Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials

Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial

Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer

Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial

Suchergebnisse filtern